

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Clover Biopharmaceuticals, Ltd.**  
**三葉草生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2197)**

**VOLUNTARY ANNOUNCEMENT**  
**CLOVER COMPLETES BLA SUBMISSION FOR SEASONAL**  
**INFLUENZA VACCINE IN BRAZIL**

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Clover Biopharmaceuticals, Ltd. (the “**Company**” or “**Clover**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors on the latest business development of the Group.

The Company is pleased to announce that the Company completes the Biologic License Application (the “**BLA**”) submission for its seasonal influenza vaccine (AdimFlu-S) to the Brazilian Health Regulatory Agency. Upon approval, the Company will work with its local partner to commercialize the product in Brazil.

If approved in Brazil, the Company’s seasonal influenza vaccine would have access to the southern hemisphere market, enabling annual sales in the first half of the year to supplement sales in the second half of the year in northern hemisphere markets such as China, while also better utilizing Adimmune Corporation’s production capacity year-round. Brazil is an important vaccine market strategically, as the country has the world’s second largest seasonal influenza vaccine market, with total local market size expected to surpass US\$1 billion over the next five years, according to GlobalData.

By order of the Board  
**Clover Biopharmaceuticals, Ltd.**  
**Dr. Peng LIANG**  
*Chairman of the Board*

Shanghai, PRC, November 7, 2023

*As of the date of this announcement, the Board comprises Dr. Peng LIANG and Mr. Joshua G LIANG as executive Directors; Dr. Xiaodong WANG, Dr. Donna Marie AMBROSINO and Dr. Ralf Leo CLEMENS as non-executive Directors; and Dr. Xiaobin WU, Mr. Xiang LIAO, Mr. Jeffrey FARROW and Mr. Thomas LEGGETT as independent non-executive Directors.*